Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical CofiledCriticalOno Pharmaceutical Co
Priority to ARP050101301priorityCriticalpatent/AR048821A1/en
Publication of AR048821A1publicationCriticalpatent/AR048821A1/en
Una preparacion de infusion la cual es util para enfermedades neurodegenerativas,la cual comprende ácido(2R)-2- propiloctanoico o una sal del mismo y un ion metálico básico el cualse suministra a partir de una sal metálica o un hidroxido metálico de ácido débil, preferiblemente de aproximadamente 1 a aproximadamente 5 equivalentes de un ion metálico básico tomando como referencia 1 equivalente de ácido(2R)-2-propiloctanoico o una sal del mismo,y opcionalmente comprende otros componentes deinfusion. La preparacion de infusion tiene un pH apropiado para administracion intravenosa, y que no requiere ninguna operacion preparatoria tal como disolucion, dilucion o similares en el momento de usoAn infusion preparation which is useful for neurodegenerative diseases, which comprises (2R) -2-propyloctanoic acid or a salt thereof and a basic metal ion which is supplied from a metal salt or a weak acid metal hydroxide, preferably from about 1 to about 5 equivalents of a basic metal ion based on 1 equivalent of (2R) -2-propyloctanoic acid or a salt thereof, and optionally comprises other infusion components. The infusion preparation has an appropriate pH for intravenous administration, and does not require any preparatory operation such as dissolution, dilution or the like at the time of use
ARP0501013012005-04-012005-04-01
"INFUSION PREPARATION THAT INCLUDES ACID (2R) -2-PROPILOCTANOIC AS AN ACTIVE AND RECENT INGREDIENT"
AR048821A1
(en)
dose of nanoparticles to a patient, method of enhancing intestinal paracellular transport or paracellular blood transport from the brain and oral dose of nanoparticles that intensifies intestinal paracellular transport or paracellular blood transport from the brain
Pharmaceutical preparation comprising (5-methyl-2-oxo-1,3-dioxol-4il) methyl 2-ethoxy-1 - {[2, {5-oxo-4,5-dihydro-1,2,4-oxadiazole -3-yl) biphenyl4yl] methyl} -1h-benzimidazol-7-carboxylate, a ph control agent between 2 and 5 and a diuretic; method to stabilize; method to improve dissolution, useful in diseases induced by angiotensin ii.
Aqueous pharmaceutical compositions comprising an ester of a prostanoid, a carboxylic acid between 1,2,1,6% dibasic sodium phosphate, sodium chloride, a solubilizing agent, and the rest of water, with a pH ranging from 4 to 8; use in eye disorders such as glaucoma, diabetic retinopathy, uveitis, among others.